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Abstract
Background and Aims: All-oral interferon-free antivirals are
highly effective in treating recurrent hepatitis C (HCV) infec-
tion in liver transplant (LT) recipients. The aim of the study
was to assess immunosuppression needs after achieving a
sustained viral response (SVR). Methods: We compared im-
munosuppression needs before and after achieving a SVR in
adult LT recipients treated for recurrent HCV infection with all-
oral direct acting agents. Results: We identified 52 liver LT
treated recipients who achieved a SVR. The median (25th and
75th percentile interquartile range [IQR]) age was 62 years
(57.75, 65). Most recipients received tacrolimus (TAC) for
their immunosuppressant regimen. After achieving SVR,
there was no statistically significant difference in daily dose
of TAC unadjusted per weight (p > 0.05). However, there was
a statistically significant decrease in daily dose of TAC
adjusted per weight, serum levels of TAC, and the product
of glomerular filtration rate and TAC. No statistically signifi-
cant differences in cyclosporine unadjusted/adjusted per
weight daily dose or serum levels were noted. Conclusions:
Immunosuppression needs were increased for those patients
treated with TAC but not cyclosporine. LTrecipients prescribed
TAC require close monitoring after treatment completion to
avoid potential risk of acute rejection.
© 2016 The Second Affiliated Hospital of Chongqing Medical
University. Published by XIA & HE Publishing Inc. All rights
reserved.
Introduction
Liver transplantation (LT) is the definitive treatment for
patients with advanced liver disease and hepatocellular carci-
noma.1–3 Initial attempts at LT in the 1960s were limited by
graft failure from cellular rejection.4–6 Advances in immuno-
suppressive therapy have led to substantial improvement in
patient and graft survival over the past several decades.7
However, the use of immunosuppressive therapy is also asso-
ciatedwith long termcomplications, suchashypertension, dia-
betes, and renal insufficiency.8–13 The goal of
immunosuppressive therapy is to maximize protection from
rejection while minimizing the adverse effects by using the
lowest dose possible.14
The most common indication for LT in the United States is
hepatitis C.15 However, recurrent HCV infection is universal,
and its progression to cirrhosis can lead to graft loss in a sig-
nificant number of LT recipients.16–18 Successful treatment of
recurrent hepatitis C virus (HCV) infection in LT recipients can
reduce the risk of subsequent HCV-related complications and
graft loss.14,17,19,20 The use of interferon to treat recurrent
HCV was associated with concerns for graft loss because of
the perceived enhanced immune modulating effects of inter-
feron.21–23 Furthermore, graft failures were found to occur
after viral suppression was achieved.21
The introduction of all-oral interferon-free antiviral therapy
has revolutionized the treatment of HCV infection. These
treatments are safe and highly effective in LT recipients with
recurrent HCV infection, thus broadening the group of patients
eligible for treatment.24–26 A direct consequence of avoiding
interferon in the treatment of recurrent HCV is the increased
number of recipients that would be eligible for the interferon-
free therapy. However, a possible unexpected consequence of
achieving viral suppression may be improved metabolism of
immunosuppressant medications, aside from direct drug-
drug interactions. For instance, the results of two recent
studies of direct acting agents highlight changes in immuno-
suppressant dosing after antiviral therapywas completed.26,27
Calcineurin inhibitors are all metabolized by the liver (cyto-
chrome P-450 3A4 system) and increased performance of
hepatic metabolism function highly influences the
bioavailability of these medications.28 With improved liver
function after HCV treatment in LT recipients, patients’ needs
for immunosuppression may change.
32 Journal of Clinical and Translational Hepatology 2016 vol. 4 | 32–38
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 Unported License,
permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: Liver transplantation; Immunosuppressant; Hepatitis C; Direct acting
agents.
Abbreviations: ALT, alanine aminotransferase; AP, alkaline phosphatase; AST,
aspartate Transaminase; BMI, body mass index; CKD-EPI, Chronic Kidney
Disease Epidemiology Collaboration Formula; CSA, cyclosporine; GFR, glomerular
filtration rate; HCV, Hepatitis C; HIV, human immunodeficiency virus; IQR, inter-
quartile range; LT, liver transplant; MELD, Model for End-Stage Liver Disease;
mTOR, mammalian target of rapamycin; SVR, sustained viral response; TAC,
tacrolimus; TDD, total daily dose; UCLA, University of California, Los Angeles
Medical Center.
Received: 5 January 2016; Revised: 19 February 2016; Accepted: 24 February
2016
qDOI: 10.14218/JCTH.2016.00001.
*Correspondence to: Sammy Saab, Pfleger Liver Institute, UCLA Medical Center,
200 Medical Plaza, Suite 214, Los Angeles, CA 90095, USA. Tel: +1-310-206-
6705, Fax: +1-310-206-4197, E-mail: SSaab@mednet.ucla.edu
The hypothesis of this study is that LT recipients who
achieve a sustained viral response (SVR) will require greater
amounts of immunosuppression. Understanding this phe-
nomenon will help to tailor strategies that will protect LT
recipients from potential graft rejection after they are cured
of HCV.
Methods
We performed a retrospective cohort study of all adult (age
>18 years) LT recipients who achieved SVR after being
treated with all-oral HCV antiviral therapy for recurrent HCV
infection at the University of California, Los Angeles Medical
Center (UCLA) between October 2011 and October 2014.
A SVR was defined as an undetectable HCV RNA 12 weeks
after treatment completion. Exclusion criteria included active
infection, biliary obstruction, and allograft rejection on biopsy
within 6 months of starting antiviral therapy.
This study was approved by the UCLA Institutional Review
Board. Patient consent was not required. Data were obtained
by medical chart review and retrieved by the UCLA Liver
Transplant database. Demographic data (age, gender, and
race/ethnicity), history of LT, history of previous HCV therapy,
nonliver related medical history (active cardiopulmonary
disease, hemodialysis, stroke, nonliver malignancy, and dia-
betes), co-existent liver disease (nonalcoholic fatty liver
disease, hepatitis B, and autoimmune hepatitis), and stage
of fibrosis, categorized as Mild (stage 0-2) and Moderate to
Severe (stage 3-4), were recorded. Fibrosis was defined by
liver biopsy, laboratory testing, and radiological imaging.
Hematologic, biochemical data, immunosuppressant levels,
and HCV RNA levels were collected prior to initiation of
antiviral therapy and after achieving a SVR.
Immunosuppressive needs
We ascertained immunosuppressant needs through a variety
of methods: 1) total daily dose of the immunosuppressant,
2) the dose of immunosuppressant per the recipient body
weight (kg), 3) product of immunosuppressant and glomer-
ular filtration rate (GFR) (Chronic Kidney Disease Epidemiol-
ogy Collaboration Formula, CKD-EPI, mL/min/1.73 m2). The
last method was chosen since it is our custom to tailor
immunosuppressant dose to GFR to avoid renal toxicity. We
compared laboratory values and computations for 3 months
before starting HCV therapy and 3 months after therapy was
completed.
Statistics
Data are presented as medians with 25th and 75th percentile
interquartile range (IQR) for continuous variables and
number within group with percent of group for discrete vari-
ables. The within patient differences in labs and medication
regiments were compared before and after treatment using
the two-sided Wilcoxon Rank Sum test. A multivariable linear
regression model with percent change in immunosuppressant
serum level as the dependent variable and percent change in
alanine aminotransferase (ALT) and weight-adjusted, total
daily dose as the independent variables was used to assess
changes in serum level with respect to medication and liver
function. p < 0.05 was considered statistically significant. The
R Statistical Computing Environment was used for data anal-
ysis (R Core Team 2015).
Results
The demographics of the study patient cohort are presented
in Table 1. Twenty-five (48.1%) recipients had at least one
nonhepatic comorbidity. Few patients had concomitant fatty
liver, and no recipients were co-infected with hepatitis B or
human immunodeficiency virus (HIV). Twenty percent of
recipients had a diagnosis of hepatocellular carcinoma prior
to LT. Most patients were infected with genotype 1 (78.8%).
The rest of patients were infected with genotypes 2, 3, and
4 (5.8%, 11.5% and 3.8%, respectively). Pretreatment
lab results were available a median (IQR) of 5 (3, 7.25)
months. The median (IQR) time from SVR12 to collection of
three laboratory values was 5 months (4, 7.25).
Tacrolimus (TAC)-based immunosuppression was used in
75% of LT recipients. The median (IQR) total daily dose,
weight-adjusted total daily dose, and serum TAC values were
2 (1.5, 4) mg, 0.03 (0.02, 0.05) mg/kg, and 8.1 (6.57, 9.1)
ng/mL, respectively. Of the recipients treated with cyclo-
sporine, the median (IQR) total daily dose, weight-adjusted
total daily dose, and serum cyclosporine was 150 (133.33,
200) mg, 1.93 (1.37, 2.81) mg/kg, and 112 (79, 128.67)
ng/mL, respectively. Fifteen percent of recipients treated with
TAC had moderate to severe fibrosis, and 39% of recipients
treated with cyclosporine had moderate to severe fibrosis.
Most recipients were taking mycophenolate before and after
achieving a SVR.
The median (IQR) aspartate aminotransferase (AST) and
ALT before achieving a SVR were 58.83 (40.66, 80.92) and
62.66 (43.67, 88.42), respectively. There was a statistically
significant improvement in all assessed liver associated tests
in LT recipients who achieved SVR12 (p < 0.05) (Table 2).
There was also a statistically significant improvement in pla-
telet count (p = 0.005). Body mass index (BMI) increased
with SVR12. The median (IQR) BMI was 26.8 (23.69,
29.78) before treatment initiation and 27.58 (23.94, 31.0)
after SVR (p = 0.012). There was no change in renal function
as measured by GFR after achieving SVR (p = 0.099).
Changes in immunosuppression need were assessed in
multiple ways (Tables 3 and 4). Most recipients treated with
TAC had a decrease in their weight adjusted total daily dose
of TAC and TAC serum levels (Table 3). There was no statisti-
cally significant change in the unadjusted total dose of TAC
(p = 0.174), but there was an observed significant decrease
in weight adjusted total dose of TAC (p = 0.001) and serum
levels of TAC after achieving SVR (p-value <0.001) (Table 4,
Figure 1a). Moreover, the product of TAC serum level and GFR
was significantly lower after SVR (p < 0.001). In contrast,
there was no significant changes in unadjusted or adjusted
total dose of cyclosporine, serum levels of cyclosporine, or
the product of cyclosporine serum level and GFR (p > 0.05)
(Table 4, Figure 1b). There was an observed interaction
between serum change of immunosuppression levels and
total daily dose immunosuppression with the percent change
of median ALT values (Figure 2). In a multivariate analysis,
there was an observed relationship between percent change
in serum levels and percent change in weight-adjusted, total
daily dose (p=0.027), but not in percent change inmedianALT
values (p = 0.226). When restricting the population to only
patients taking TAC, the relationship was significant between
change in serum levels and weight-adjusted total daily dose
(p= 0.014) and change in serum levels and change in median
ALTvalues (p = 0.022).
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Discussion
The results of our study demonstrate that LT recipients
immunosuppression needs may increase after achieving a
SVR. The goal of immunosuppression in LT is to minimize
clinically significant side effects and to prevent rejection.28–32
Immunosuppression regimens are tailored based on multiple
factors, including renal and hepatic function, and may require
frequent adjustments by providers to tailor them to the indi-
vidual patient. Therefore, the clinical implication of our study
is that LT recipient’s status post-recurrent HCV treatment may
be at increased risk of rejection.
Our results are consistent with prior observations made by
others. Kwo et al. found that eight out of 34 LT recipients
required adjustments of their immunosuppressant shortly
after completing their antiviral therapy.26 Although there is a
significant drug-drug interaction between the 3D regimen,
TAC, and cyclosporine, and the immunosuppressant trough
levels were mostly stabilized several weeks after initiation of
the 3D regimen, these observations were made after com-
pleting therapy.33 Likewise, Chartlon et al. described 25 of
229 LT recipients who required dose adjustments after com-
pleting a course of antiviral therapy, but the direction of the
change was not characterized.27
We speculate that improvement in liver function with
interferon-free therapy may explain the increased need for
immunosuppression. In patients with recurrent HCV post-
transplantation, treatment with interferon-free therapy
resulted in early post-treatment liver function improvement,
as evidenced by decreases in bilirubin and Model for End-
Stage Liver Disease (MELD) scores and increases in
albumin.34,35 Improved metabolic function of the liver may
explain our results. Calcineurin inhibitors, mammalian target
of rapamycin (mTOR) inhibitors, and antimetabolites are
metabolized by the liver (cytochrome P-450 3A4 system),
and performance of hepatic metabolism function highly influ-
ences the bioavailability of these agents.28 An important
finding of our study is the differential effect of curing HCV on
Table 1. Demographic and baseline values
Variable All Tacrolimus Cyclosporine
Number of patients 52 39 13
Age, median (interquartile range) 62 (58,65) 62 (58,65) 60 (55,63)
Gender
Male (%) 42 (80.77) 31 (79.49) 11 (84.62)
Ethnicity
Hispanic (%) 18 (34.62) 12 (30.77) 6 (46.15)
Non-Hispanic White (%) 16 (30.77) 11 (28.21) 5 (38.46)
Other (%) 18 (34.62) 16 (41.03) 2 (15.38)
Body Mass Index (kg/m2), median (interquartile range) 26.8 (23.69,
29.78)
25.73 (23.23,
29.55)
28.59 (25.58, 30.94)
Months since liver transplant, median (interquartile
range)
32.9 (13.78,
74.42)
29.18 (13.09,
60.82)
59.24 (39.63,
179.60)
Mycophenolate
Before Treatment 36 (69.23) 29 (74.36) 7 (53.85)
After Treatment 35 (67.31) 26 (66.67) 9 (69.23)
Sirolimus
Before Treatment 1 (1.92) 0 (0) 1 (7.69)
After Treatment 2 (3.85) 1 (2.56) 1 (7.69)
Hepatitis C Treatment Experienced (%) 23 (44.2) 14 (35.9) 9 (69.2)
Antiviral Therapy
Sofosbuir/Ribavirin (%) 31 (59.6) 23 (59) 8 (61.5)
Sofosbuir/Simeprevir (%) 21 (40.4) 16 (41) 5 (38.5)
Non-hepatic comorbidities
Cardiac disease (%) 5 (9.6) 5 (12.8) 0 (0)
Hemodialysis (%) 3 (5.77) 2 (5.13) 1 (7.69)
Cerebral vascular stroke (%) 1 (1.92) 1 (2.56) 0 (0)
Non-liver malignancy (%) 5 (9.6) 4 (10.3) 1 (7.69)
Diabetes (%) 17 (32.69) 13 (33.33) 4 (30.77)
Lymphoma (Non-PTLD) (%) 1 (1.92) 0 (0) 1 (7.7)
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TAC and cyclosporine levels. One possible explanation could
be that the serum concentration of cyclosporine is 15-fold
higher than that of TAC (112 ng/ml vs 8.1 ng/ml, respec-
tively) and that cyclosporine, but not TAC, has a pharmacoki-
netics inhibitory effect on hepatic CYP metabolic enzymes.36
In addition, restoration of host immune response by
interferon-free therapy may also explain this phenomenon.
In chronic hepatitis C infection, HCV renders the host’s virus-
specific CD8+ T cells dysfunctional and transient by several
mechanisms, such as viral escape and T-cell exhaustion.37,38
Previously, interferon-based therapies failed to recover HCV-
specific CD8+ Tcell functions.39,40 However, in a recent study
with IFN-free therapies (faldaprevir and deleobuvir), prolifer-
ative HCV-specific CD8+ T cells were rapidly restored in the
majority of patients (n/N = 19/22, 86.4%).3 In contrast,
HCV-specific CD8+ T cells did not increase in patients with
treatment failure. This finding suggests that adaptive immun-
ity after successful HCV treatment is restored and may
require immunosuppression adjustment to prevent graft
rejection.
In addition, successful HCV therapy can lead to removal of
the immunosuppressive effect from HCV itself. In a few LT
recipients, immunosuppressive medication may not be
required after sometime due to a phenomenon called “trans-
plant tolerance.”29,41 Its mechanism is not completely under-
stood, but the current hypothesis is that HCV infection
induces immunoregulation and facilitates “transplant toler-
ance,” leading to successful discontinuation of immunosup-
pression.41 In contrast, a successful eradication of the
immunosuppressive effect of HCV may lead to a heightened
Table 2. Changes in clinical and laboratory parameters before and after achieving a sustained viral response. Data are presented as a median with
interquartile range in parenthesis for continuous variables
Parameter Before After Within patient difference P-value
Clinical
BMI (kg/m2) 26.8 (23.685, 29.777) 27.58 (23.94, 31.003) 0.46 (−0.153, 1.588) 0.012
Laboratory
Hemoglobin (g/dL) 12.84 (11.047, 14.803) 13.435 (11.793, 14.72) 0.48 (−0.592, 1.462) 0.111
Platelet Count
(x10E3/mL)
121.335 (77.875,
147.92)
136.835 (104.082,
159.67)
11.835 (−5.165, 34.915) 0.005
SCL (mg/dL) 1.13 (0.908, 1.355) 1.115 (0.918, 1.36) 0.03 (−0.1, 0.15) 0.412
Albumin (g/dL) 4.07 (3.73, 4.3) 4.37 (4.17, 4.508) 0.215 (0.07, 0.515) < 0.001
AST (U/L) 58.83 (40.665, 80.918) 24.665 (18.67, 30.415) −27.335 (−54.165,−14.082) < 0.001
ALT (U/L) 62.665 (43.668, 88.418) 21.665 (16, 33.415) −34.835 (−65.08, −15.668) < 0.001
Biliburin, total
(mg/dL)
0.95 (0.73, 1.178) 0.7 (0.53, 0.948) −0.215 (−0.4, −0.06) < 0.001
AP (U/L) 96.5 (73.75, 134.502) 84.665 (63.75, 117.418) −14.835 (−28.338, −0.077) 0.001
GFR
(mL/min/1.73 m2)
65 (53, 80.498) 62 (48.502, 78.33) −1.67 (−8.33, 3.25) 0.099
Abbreviations: BMI, body mass index; SCL, creatinine; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AP, alkaline phosphatase; GFR, glomerular filtration
rate.
Table 3. Changes in immunosuppressant parameters
Variable All (n = 52)
Tacrolimus
(n = 39)
Cyclosporine
(n = 13)
Total Immunosuppressant Daily Dose
Decrease 19 (36.5%) 16 (41%) 3 (23.1%)
Equivalent 18 (34.6%) 14 (35.9%) 4 (30.8%)
Increase 15 (28.9%) 9 (23.1%) 6 (46.2%)
Total Immunosuppressant Daily Dose/Weight (kg)
Decrease 34 (65.38%) 29 (74.36%) 5 (38.46%)
Equivalent 2 (3.85%) 1 (2.56%) 1 (7.69%)
Increase 16 (30.77%) 9 (23.08%) 7 (53.85%)
Immunosuppressant Serum Level
Decrease 35 (67.31%) 31 (79.49%) 4 (30.77%)
Equivalent 0 (0%) 0 (0%) 0 (0%)
Increase 17 (32.69%) 8 (20.51%) 9 (69.23%)
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immunity in LT recipients. Hence, the immunosuppressants
may need to be increased accordingly, following the treat-
ment HCV infection.
There are a number of important limitations to our study.
First, the study is retrospective, and laboratory test results
were not collected using a systematic approach. Nevertheless,
this is one of the largest analyses performed on HCV therapy
among LTrecipients that is applicable and generalizable across
several different antiviral regimens. A prospective trial with
different antiviral regimens and a systematic laboratory col-
lection would be helpful to clarify this intricate relationship
between HCV therapy and immunosuppression. Second,
there is no ideal method to estimate immunosuppressant
needs. Dosing of TAC and cyclosporine is not standardized
and is adjusted based on multiple factors, including renal
function, BMI, and individual provider judgment. We chose
several novel parameters (total daily dose of the immunosup-
pressant, the dose of immunosuppressant per the recipient
body weight, and product of immunosuppressant and GFR) to
estimate immunosuppressant needs in our study. Nonethe-
less, the results were consistent across all the measured and
calculated parameters.
In our study, curing HCV infection in LT recipients resulted
in greater immunosuppression needs. Given the availability,
tolerability, and success of all-oral interferon-free antiviral
regimens, practitioners should be aware of this potential,
unanticipated side effect to prevent graft loss. They may
consider more frequent and closer monitoring of immunosup-
pression levels 12 weeks after SVR.
Table 4. Changes in immunosuppressant parameters before and after achieving a sustained viral response. Data are presented as a median with
interquartile range in parenthesis for continuous variables
Parameter Before After Within patient difference P-value
Tacrolimus
TAC TDD (mg) 2 (1.5, 4) 2.167 (1.583, 3.75) 0 (−0.667, 0) 0.174
TAC TDD
(mg)/Weight (kg)
0.03 (0.019, 0.049) 0.029 (0.019, 0.045) −0.002 (−0.009, 0) 0.011
GFR X TAC
(mL/min/1.73 m23mg)
507.5 (362.285, 615.85) 348 (216.185, 458.5) −147.57 (−281.65, −103.235) < 0.001
FK Serum Level
(ng/mL)
8.1 (6.57, 9.1) 5.13 (3.965, 6.685) −2.4 (−4.27, −1.25) < 0.001
Cyclosporine
CSA TDD (mg) 150 (133.333, 200) 166.667 (133.333, 200) 0 (0, 25) 0.905
CSA TDD
(mg)/Weight (kg)
1.935 (1.368, 2.813) 2.1 (1.531, 2.841) 0.153 (−0.063, 0.302) 0.505
CSA Serum Level
(ng/mL)
112 (79, 128.67) 105.67 (77, 128.33) 5.76 (−15.34, 15) 0.78
GFR X CSA
(mL/min/1.73 m2 3 mg
6286.67 (5059, 6720.6) 5563.33 (5271,
6638.83)
212 (−1513.66, 815.66) 0.944
Abbreviations: TAC, tacrolimus; CSA, cyclosporine; GFR, glomerular filtration rate; TDD, total daily dose.
Fig. 1. Tacrolimus (A) and cyclosporine (B) serum levels before and after
achieving a sustained viral response.
Fig. 2. Alanine transferase (ALT), serum, and total daily dose (TDD) of
immunosuppression for both immunosuppressant medications.
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